ISRCTN82505455进行中（未招募）未知
Activity as medicine in oncology for head and neck
niversity of Liverpool0 个研究点目标入组 70 人开始时间: 2022年8月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 70
研究概览
简要总结
2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/37624789/ (added 29/08/2023)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. >= 16-year-old.
- •2. Able to provide informed consent.
- •3. Diagnosed with HaNC for treatment with curative intent.
- •4. Between time of diagnosis and up to 8 weeks post-treatment.
- •5. Classified as low-medium risk according to an exercise risk stratification tool.
排除标准
- •1. Treated with palliative intent, as decided by the HNC multidisciplinary team.
- •2. Classified as high risk according to an exercise risk stratification tool, or has any other unstable or uncontrolled medical condition associated with increased risk during exercise.
- •3. Unable to provide informed consent.
研究者
相似试验
已完成
Unknown
Clinical practices in head and neck cancer: the role of the speech and language pathologist in assessment and management of swallowing disorders in patients treated with radiotherapy in FlandersDysphagia management in head and neck cancer patients treated with radiotherapy in FlandersCancerISRCTN47855281Ghent University Hospital10
进行中（未招募）
1 期
T4 immunotherapy of head and neck cancerCancerISRCTN81726461King's College London25
招募中
3 期
a Multicentre Phase III Study of Risk-based Treatment Intensification With Hyperfractionated Radiotherapy in Head and Neck Cancer PatientsHead and Neck Squamous Cell CarcinomaNCT06248996Lund University Hospital308
终止
3 期
EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck CancerOral MucositisHead and Neck CancerNCT00574860Endo Pharmaceuticals240
已完成
不适用
Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and CanadaHead and Neck CancerNCT02705833Bristol-Myers Squibb591